Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cerium Oxide,Tolfenamic Acid
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Cerium Oxide,Tolfenamic Acid
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolfenamic Acid
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2020
Lead Product(s) : Tolfenamic Acid
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolfenamic Acid
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2014
Lead Product(s) : Tolfenamic Acid
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable